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Background: There is a controversy regarding Latent Autoimmune Diabetes in
Adults (LADA) classiﬁcation and whether it should be considered a slowly
progressing form of type 1 (T1) diabetes (DM) or a distinct type of DM
altogether.
Methods: This cross-sectional study assessed major genes associated with
T1DM (class II HLA, PTPN22 [rs2476601] and INS [rs689]) in patients with LADA,
as compared with participants with T1DM (stratiﬁed according to age of diagnosis
before or after 30) and T2DM. HLA genotyping of the DRB1, DQA1 and DQB1 loci
was performed by reverse PCR sequence-speciﬁc oligonucleotides. HLA
haplotypes were assigned according to those most frequently described in the
European population. INS and PTPN22 SNPs were genotyped by real-time PCR.
Results: A total of 578 participants were included: 248 with T1DM (70
diagnosed after the age of 30), 256 with T2DM and 74 with LADA. High risk
HLA alleles were signiﬁcantly more frequent in LADA than in T2DM, whereas
the opposite was true for protective alleles. We found a lower frequency of the
high-risk DRB1*04-DQB1*03:02-DQA1*03:01 haplotype in LADA (21.1%) than
in the overall T1DM (34.7%) (p<0.05), whereas no differences were found
between these groups for DRB1*03-DQB1*02:01-DQA1*05:01 or for
protective alleles. Only 12% the overall T1DM group had no risk alleles vs 30%
of LADA (p<0.0005). However, HLA allele distribution was similar in LADA and
T1DM diagnosed after the age of 30. A total of 506 individuals (195 with T1DM
[21 diagnosed after age 30] 253 with T2DM and 58 with LADA) were genotyped
for the PTPN22 and INS SNPs. The G/A genotype of the PTPN22 rs2476601 was
more frequent and the T/T genotype of the INS SNP rs689 was less frequent in
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T1DM compared to LADA. We did not ﬁnd any signiﬁcant differences in the
frequency of the mentioned SNPs between LADA and T2DM, or between LADA
and T1DM diagnosed after the age of 30.
Conclusion: In this relatively small cross-sectional study, the genetic proﬁle of
subjects with LADA showed a similar T1DM-related risk allele distribution as in
participants with T1DM diagnosed after the age of 30, but fewer risk alleles than
those diagnosed before 30. Differences were present for HLA, as well as
PTPN22 and INS genes.
KEYWORDS

LADA (latent autoimmune diabetes in adults), genetics, HLA class II, PTPN22, Type 1
diabetes mellitus, INS, age of onset

Introduction

In the present study, we evaluated differences in the HLA
region, as well as in PTPN22 and INS, in patients diagnosed with
LADA compared to patients diagnosed with T1DM and T2DM.

Latent Autoimmune Diabetes in Adults (LADA) is a slowly
progressive autoimmune form of diabetes presenting in adults.
There is still debate regarding its classiﬁcation and whether it
should be considered a slowly progressing form of type 1 (T1)
diabetes mellitus (DM) or a distinct type of DM (1). A recent
consensus statement from the American Diabetes Association
and the European Association for the Study of Diabetes (EASD)
deﬁnes age of onset (>30 years), presence of diabetes associated
autoantibodies and absence of insulin requirements for at least 6
months after diagnosis as key diagnostic criteria for LADA (2).
Also, they recommend an individualized approach that differs
from the classical management of T1DM.
It has been shown that individuals with LADA have a
distinct metabolic proﬁle compared to patients with T1DM
and type 2 (T2) DM, with higher C-peptide concentrations
than subjects with T1DM and a lower frequency of metabolic
syndrome than people with T2DM (3). In addition, there is some
evidence that LADA is associated with a genetic background that
is different from T1DM and T2DM, with an attenuated inﬂuence
of key T1DM-associated HLA haplotypes compared to T1DM
and an increased presence of PTPN22, INS and SH2B3
polymorphisms, compared to T2DM (4).
The PTPN22 gene encodes a protein tyrosine phosphatase, a
negative regulator for T cell activation, and a down-regulator of
the immune response. The ﬁrst study on the association between
PTPN22 gene variants with T1DM was reported by Bottini et al
(5) in 2004. Among the single nucleotide polymorphisms (SNPs)
in the gene, rs2476601 has been linked to T1DM (4, 6). The INS
gene encodes the (pro) insulin protein. Variants in the gene or its
promotor region might affect its thymic expression, leading to
decreased tolerance and a higher likelihood of developing an
autoimmune response (7).

Frontiers in Endocrinology

Methods
Design and setting
This is a cross-sectional study, performed in Catalonia,
Spain, assessing the major genes associated with T1DM in
patients with LADA, as compared with individuals with
T1DM and T2DM. It was part of a more comprehensive
study, characterizing LADA in our population (3, 8). The
study was designed in 2006. PTPN22 and INS, along with
HLA, were selected because they were at that time among the
genes described to have more weight in the development of
T1DM in genetic association studies (9).

Patients
We included patients diagnosed with different forms of
DM and different age groups. T1DM and T2DM were
diagnosed according to standard criteria (1). GAD-antibody
screening was performed in all participants. If they were
positive, they were not classiﬁed as T2DM. Participants with
T1DM were classiﬁed according to an age of onset of below or
above 30 years of age. Patients with DM (both T1DM and
LADA) diagnosed after the age of 30 years of age were recruited
from two hospital-based centers in northeastern Spain
(Barcelona and Lleida). The patients with T1DM diagnosed
before 30 years of age were those entered in the Catalonian
T1DM registry between January 1, 1987 and December 31,
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1988 (10). Cases of LADA were deﬁned as patients aged 30–70
years at the time of diagnosis of diabetes who did not require
insulin for at least 6 months after diagnosis, with glutamic acid
decarboxylase (GAD) autoantibody (GADAb) or tyrosine
phosphatase autoantibody (IA-2Ab) positivity, as described
in previous studies (3). All patients were included, at least, 6
months after diagnosis. Most LADA patients were diagnosed
clinically, and further conﬁrmed by GAD-antibody
measurement at the reference hospital. The rest were
identiﬁed in primary care among people with a clinical
diagnosis of T2DM, after systematic antibody measurement
as part of a larger study (8).
Samples from controls for the genetic analysis of PTPN22
and INS genes were obtained from umbilical cord blood samples
from the Barcelona Cord Blood Bank in 2009.

Statistical analysis
Sample size estimations were done for the T1DM group as a
whole. Indeed, the study was designed to detect an absolute 13%
difference between groups in the absence of high-risk haplotypes
[expected to be 13% in the participants with T1DM, 26% in the
LADA group and 40% in the T2DM group] with a 95%
conﬁdence. This led to an estimation of 80 participants with
LADA, 218 with T2DM and 256 with T1DM.A descriptive
analysis was performed using percentages for qualitative
variables and mean (standard deviation [SD]) or median (interquartile range [IQR]) for continuous variables, according to
whether their distribution was Gaussian or not, respectively.
Groups were compared using the Student’s t test or the MannWhitney U test (pairwise comparisons) and ANOVA or KruskalWallis tests for continuous variables and chi-squared and Fisher’s
test, as appropriate, for percentages. Hardy-Weinberg Equilibrium
was assessed for the SNPs in PTPN22 and INS and comparisons
were made using the dominant, codominant, recessive and
additive models, if possible. Results were expressed as odds
ratios and 95% conﬁdence intervals (OR [95% CI]). Both
unadjusted and (age and BMI) adjusted comparisons (using a
general linear model) were performed. Results were considered
statistically signiﬁcant if p was below 0.05
The study was approved by the Ethics Committees of
Hospital de la Santa Creu i Sant Pau, Barcelona and Hospital
Universitari Arnau de Vilanova, Lleida.

Genetics
Automated DNA extraction was performed using the
Maxwell instrument (Promega, Madison, Wisconsin, USA).
HLA genotyping of the DRB1, DQA1 and DQB1 loci was
performe d by r everse PCR-SSO (sequence-speci ﬁc
oligonucleotides) using INNO-LiPA HLA typing kits
(Innogenetics, Fujirebio Europe N.V., Ghent, Belgium). Highrisk and protective HLA-DRB1 alleles were determined by low
resolution (1-ﬁeld) genotyping, while DQB1 and DQA1 loci were
typiﬁed by 2-ﬁeld high resolution genotyping. HLA haplotypes
were assigned according to the most frequent haplotypes
described in European populations (11).
INS and PTPN22 SNPs were genotyped using an in-house
technique by real-time PCR on a LightCycler 480 PCR system
(Roche Diagnostics, Basel, Switzerland) using FRET probes.
Primer and probe sequences are shown in Table 1. The −23
HphI polymorphism (rs689) was genotyped as a surrogate
marker for the INS-VNTR, based on the almost complete
linkage disequilibrium between them (12) (the −23 HphI A
allele corresponds to VNTR class I and the −23 HphI T allele
corresponds to VNTR class III). In PTPN22, the SNP Arg620Trp
(rs2476601) was genotyped.

Results
A total of 578 participants were included: 248 with T1DM
(178 diagnosed below 30 years of age and 70 above that age), 256
with T2DM and 74 with LADA. Their main features are
displayed in Table 2.

Characterization
Patients with T1DM were signiﬁcantly younger compared to
patients with T2DM and LADA. Patients diagnosed with LADA

TABLE 1 Primers and probes used for INS and PTPN22 genotyping.

Name

Sequence

5’ Mod.

rs689_F

CAGCAGGGAGGACGTGGC

rs689_R

CCCCGCACACTAGGTAGAGA

rs689_anchor

GCCTTCAGCCTGCCTCAGCCCT

rs689s_sensor

CCTGTCACCCAGATCAC

rs2476601_F

CCTCAAACTCAAGGCTC

rs2476601_R

CCTTTGGATTGTTCTAATTAAC

rs2476601_anchor

AATCATTTATTGTGGTTGAGGAAGCT

rs2476601_sensor

ACTTCCTGTACGGACACCT

Frontiers in Endocrinology

3’ Mod.

6-FAM-Q
Cy-5

Cy-5

Phos

Phos
6-FAM-Q
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TABLE 2 Characterization of the participants according to type of diabetes.

T1DM<30

T1DM>30

LADA

T2DM

178

70

74

256

91 (51.1)

32 (45.7)

28 (38.3)

98 (37.8)

Age (years)

29.5 (8.6)*

47.9 (12.3)*

54.2 (12.2)

55.9 (9.3)*

Diabetes duration (years)

13.3 (5.9)*

5.4 (5)

5.2 (6.6)

2.7 (2.3)*

Waist circumference (cm)

87.2 (9.9)*

90.5 (12.7)

94.3 (12.1)

101.7 (13.6)*

Body Mass Index (Kg/m2)

22.1 (3.6)

25.7 (5.9)

26.5 (4.2)

30 (5.6)

N
Female sex [n (%)]

Continuous variables are expressed as mean (standard deviation) T1DM<30: type 1 diabetes diagnosed before the age of 30. T1DM>30: type 1 diabetes diagnosed after the age of 30. *p ≤
0.004 compared with LADA. T1DM, Type 1 Diabetes Mellitus; LADA, Latent Autoimmune Diabetes of the Adult; T2DM, Type 2 Diabetes Mellitus.

frequent in T1DM than in LADA (p = 0.06). The absence of
risk alleles, however, was more frequent in LADA than in T1DM
(30.3% vs 12%) (p <0.001).
When comparing the LADA and T2DM groups, we found a
higher frequency of the T1DM risk haplotype DRB1*03DQB1*02:01-DQA1*05:01 in the former (48.7% vs 18.8%; p
<0.001), as well as a decreased frequency of the protective
haplotype DRB1*15-DQA1*01:02-DQB1*06:02 (5.3% vs 18%,
p <0.01).
Finally, a third sub analysis comparing the HLA risk and
protective alleles in patients diagnosed with LADA vs T1DM
diagnosed after 30 years of age found no differences between
both groups.

also had a longer time since diagnosis compared to patients
diagnosed with T2DM and those diagnosed with T1DM before
the age of 30. Anthropometrical measurements in the
participants with LADA showed values that fell between
T1DM and T2DM (see Table 2).

HLA analysis
Table 3 summarizes the results of HLA genotyping. In a ﬁrst
analysis, we compared the frequency of HLA risk alleles between
patients diagnosed with LADA (n = 74) and with T1DM (n =
248). We found a lower frequency of the DRB1*04-DQB1*03:02DQA*03:01 allele in LADA (21.1%) vs T1DM (34.7%) (p <0.05).
No differences were found regarding the frequency of DRB1*03DQB1*02:01-DQA1*05:01 between these groups. No difference
was found regarding the frequency of the protective alleles
(DRB1*15-DQA1*01:02-DQB1*06:02) either. The presence of
both risk haplotypes in the same individual (DRB1*03DQB1*02:01/DRB1*04-DQB1*03:02) tended to be more

PTPN22 and INS
Table 4 summarizes the results of the PTPN22 and INS SNP
genotyping. Regarding PTPN22 (rs2476601), the minor allele
(T) frequency was 0.0432 in controls and the genotype

TABLE 3 HLA allele and haplotype distribution among groups.

T1DM<30 T1DM>30
N

%

N

%

T1DM
(total)

T2DM

LADA

N

N

N

%

%

%

T1DM vs.
LADA

T2DM vs.
LADA

T1DM>30 vs.
LADA

p-value

p-value

p-value
0.087

DRB1*04

92

51.7%

33

45.2% 125 49.8%

71 27.8% 24 31.6%

0.005

0.527

DRB1*04-DQB1*03:02

83

46.6%

30

41.1% 113 45.0%

58 22.7% 22 28.9%

0.013

0.268

0.120

DRB1*04-DQB1*03:02DQA1*03:01

65

36.5%

22

30.1%

87 34.7%

44 17.3% 16 21.1%

0.039

0.157

0.318

DRB1*03-DQB1*02:01DQA1*05:01

119

66.9%

28

38.4% 147 58.6%

48 18.8% 37 48.7%

0.128

<0.001

0.204

DQA1*03:01-DQA1*05:01

34

19.1%

5

6.8%

39 15.5%

9

3.5%

5

6.6%

0.045

0.246

0.947

DRB1*03–DQB1*02:01/DRB1*04DQB1*03:02

43

24.2%

7

9.6%

50 19.9%

13

5.1%

8 10.5%

0.060

0.088

0.849

DRB1*15

4

2.2%

4

5.5%

8

3.2%

54 21.2%

4

5.3%

0.399

0.001

0.953

DRB1*15–DQA1*01:02DQB1*06:02

2

1.1%

2

2.7%

4

1.6%

46 18.0%

4

5.3%

0.088

0.006

0.681

11

6.2%

19

26.0%

30 12.0% 149 58.4% 23 30.3%

<0.001

<0.001

0.566

No risk alleles**

**: no DRB1*03 or DRB1*04 or DQB1*02:01 or DQB1*03:02;
T1DM, Type 1 Diabetes Mellitus; LADA, Latent Autoimmune Diabetes of the Adult; T2DM, Type 2 Diabetes Mellitus.
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viral infections, nutritional practices or increased BMI (14). In
this context, LADA seems to be one of the lowest risk forms of
autoimmune diabetes, presenting at a later age. Still, it is worth
mentioning that LADA also shows a “spectrum” of presentation,
with age of onset having been associated with the genetic risk
(15) or GAD antibody titers (16). As Desai et al. phrased it,
“supporting the hypothesis that autoimmune diabetes occurring
in adults is an age-related extension of the pathophysiological
process presenting as childhood-onset T1DM” (15).
To our knowledge, this is one of the ﬁrst genetic studies to
directly compare LADA and T1DM diagnosed after the age of
30. Indeed, previous genetic studies comparing LADA and
T1DM are scarce overall. Other strengths of this study include
the relatively large population and the adjustment for potential
confounders (age and BMI).
As genetic analysis has become more accessible to medical
and research centers around the world, the number of studies
evaluating the genetic differences between the subtypes of DM
has increased in recent years, providing novel insights into the
pathogenic routes of the disease. In 2018, Cousminer et al (4)
published the ﬁrst Genome Wide Association Study (GWAS) in
subjects with LADA (see Table 5), whom they compared not
only to healthy controls, but also to patients diagnosed with
T1DM and T2DM. They showed mixed genetic inﬂuence,
sharing risk loci with both T1DM and T2DM. Compared to
T1DM, the only signiﬁcant differences were found in the HLA
region, with LADA showing lower frequencies of high T1DM
risk alleles. Compared to T2DM, LADA patients showed an
increased frequency of T1DM risk alleles in HLA, INS (rs689),
PTPN22 (rs2476601) and SHB3 (rs3184504). Similar results
were published by Buzzetti et al. in 2007 (23), reporting higher
frequencies of moderate and high risk class II HLA haplotypes in
subjects diagnosed with LADA compared with patients
diagnosed with T2DM.
In the present study, the patients diagnosed with T1DM
overall also showed a higher frequency of the HLA risk
haplotype DRB1*04-DQB1*03:02-DQA1*03:01 compared to

distribution did not signiﬁcantly depart from the Hardy
Weinberg equilibrium (chi-squared 0.002). When comparisons
were made between subjects with LADA and other groups, the T
allele was present more frequently in patients with T1DM (both
overall and those diagnosed before 30 years of age), than in
controls and patients with T2DM and LADA. We did not ﬁnd
any signiﬁcant differences in genotype distribution between
T2DM and LADA, nor between T1DM diagnosed after the
age of 30 and LADA in any of the models assessed.
Regarding INS (rs689), the frequency of the minor allele (T)
in controls was 0.294, and the genotype distribution did not
signiﬁcantly depart from the Hardy-Weinberg equilibrium (chisquared 0.0003). Patients diagnosed with T1DM before 30 years
of age showed signiﬁcantly more risk (A) alleles than the LADA
group, both using the recessive and the dominant models,
whereas T2DM showed fewer risk alleles, and a similar
genotype distribution to controls. No signiﬁcant differences
were found between patients with LADA and those with
T1DM diagnosed after the age of 30 using any of the models.

Discussion
Our results show genetic differences between T1DM and
LADA in all the analyzed genes (HLA, PTPN22 and INS), but
only in patients with T1DM diagnosed before 30 years of age.
However, no signiﬁcant differences were found between LADA
and the group with T1DM diagnosed after the age of 30. When
compared with T2DM, LADA patients had similar or higher
frequencies of T1DM risk alleles.
The role of high risk alleles in the age of diagnosis of
autoimmune diabetes has been previously studied by other
authors, suggesting an earlier onset in those patients with the
highest risk alleles (13), thus establishing a continuum from the
pediatric age to adulthood. Still, environmental factors can alter
this “continuum”, favoring earlier onset in those patients with
lower genetic risk exposed to environmental triggers (12) such as

TABLE 4 Polymorphisms in PTPN22 and INS gene analysis in samples from controls (umbilical cord) and patients diagnosed with T1DM before
(T1DM<30) and after 30 years of age (T1DM>30), LADA and T2DM.

Gene

PTPN22

INS

SNP

Umbilical Cord

T1DM<30*

T1DM>30

LADA

T2DM

C/C

224 (91.4%)

127 (73.0%)

16 (76.2%)

50 (86.2%)

220 (87%)

C/T

21 (8.6%)

46 (26.4%)

5 (23.8%)

8 (13.8)

32 (12.6%)

T/T

0 (0%)

1 (0.6%)

0 (0%)

0 (0%)

1 (0.4%)

A/A

123 (50.2%)

115 (66.1%)

12 (57.1%)

32 (55.2%)

121(47.8%)

A/T

100 (40.8%)

55 (31.6%)

8 (38.1%)

20 (34.5%)

106 (41.9%)

T/T

22 (9.0%)

4 (2.3%)

1 (4.8%)

6 (10.3%)

26 (10.6%)

*distribution among genotypes is signiﬁcantly different (p<0.05) from LADA.
SNP: single nucleotide polymorphism; PTPN22: Protein Tyrosine Phosphatase Non-Receptor Type 22 gene; INS: Insulin gene; T1DM: Type 1 Diabetes Mellitus; LADA: Latent
Autoimmune Diabetes of the Adult; T2DM: Type 2 Diabetes Mellitus.
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TABLE 5 Studies assessing HLA, PTPN22 and INS in LADA, type 1 and type 2 diabetes.

PTPN22 (rs2476601)*

INS (rs689)

Author

Year

Type of
article.
Population

Cervin et
al. (17)

2008

Original.
Sweden

T1DM (718),
LADA (361),
T2DM (1676) &
healthy controls
(1704)

Similar high-risk HLA in LADA vs T1DM.
Increased protective HLA in LADA vs T1DM

Risk genotypes (CT/TT)
increased in both T1DM and
LADA vs controls

Risk genotype (AA)
increased in T1DM and
LADA vs controls

Pettersen et 2010
al. (16)

Original.
Norway

T1DM (120),
LADA (126),
T2DM (1090) &
healthy controls
(1503)

Risk haplotype decreased and protective
haplotype increased in the following order:
early T1D–late T1DM–high antiGAD LADA–
low antiGAD LADA–T2DM–control

Associated with T1DM but not
with LADA

Associated with T1DM
but not with LADA

Andersen
et al. (18)

2010

Original.
Finland

T1DM>35y (257),
T2DM & LADA
(213)

Risk genotypes more frequent in T1DM vs
LADA, and in LADA vs T2DM

Risk genotypes more frequent in Risk genotypes linked to
T1DM vs LADA, and in LADA T1DM. No difference in
vs T2DM
LADA vs T2DM

Weber et
al. (19)

2010

Original.
Czech
Republic

T1DM>35y (41),
LADA (61) &
healthy controls
(99)

High risk alleles (DRB1*03, 04) more frequent
in T1DM vs LADA and vs controls

————————

————————

Kisand et
al. (20)

2012

Original.
Estonia

T1DM (154),
T2DM (260),
LADA (65) &
healthy controls
(229)

LADA associated with T1DM protective
haplotypes

Increased risk of T1DM (T/T
OR=7.2) vs controls. No effect
found on LADA

Protective for T1DM (T/
T phenotype, OR=0.06).
No effect on LADA

Okruszko
et al. (13)

2012

Original.
Poland

T1DM (175),
LADA (80) &
healthy controls
(151)

Frequency of high-risk genotypes decreased
with age for both <T1DM and LADA.
Protective genotypes increased with age

T/T genotype was more
frequent in T1DM and LADA
vs controls. Increased frequency
with age in T1DM

————————

Dong et al.
(21)

2014

Meta-analysis

6 studies:
PTPN22: LADA
(1088) & controls
(4079)

————————

T allele increased risk of LADA
vs controls (OR=1.52).
Homozygous (T/T), OR=1.86;
heterozygous (C/T), OR=1.52.

————————

Cousminer
et al. (4)

2018

GWAS
European

LADA (2634) &
controls (5947)
LADA (2454) &
T1DM (968)
LADA (2779) &
T2DM (10396)

LADA showed lower frequencies of T1DM
risk HLA alleles

Increased frequency in T1DM
and LADA vs T2DM. No
difference between T1DM and
LADA.

Higher frequency in
T1DM and LADA vs
T2DM. No difference
between T1DM and
LADA.

Ramu et al. 2019
(22)

Meta-analysis

16 studies.
PTPN22: LADA
(3187) & controls
(7480)
INS: LADA (4073)
& controls (8307)

————————

T allele increased risk of LADA
vs controls (OR=1.6). In
homozygous (T/T) the risk
increased (OR=2.67)

T allele protective for
LADA (OR=0.6).
In homozygous (T/T),
OR=0.43; in heterozygous
(A/T), OR=0.53

Buzzeti et
al. (23)

Original. Italy

T2DM (382) &
LADA (191)

Higher frequency of moderate and high risk
HLA class II haplotypes in LADA (22.5% and
8.4% respectively) compared with T2DM
(11.2% and 1.2% respectively)

————————

————————

2007

Subjects
(Diagnosis
(N))

HLA

*Some authors mention the T allele to express the risk, and others mention the complementary nucleotide A. T is used throughout the table and text, for clarity’s sake. T1DM, type 1
diabetes; T2DM, type 2 diabetes.

Kisand et al. (20) also reported differences in HLA risk alleles
between T1DM (mean age 22 years) and LADA in an Estonian
population, i.e. an increased prevalence of T1DM HLA
protective haplotypes in patients with LADA. This ﬁnding is
in accordance with earlier studies suggesting that the increased

LADA. Furthermore, the absence of risk alleles was more
frequent in patients diagnosed with LADA than in patients
diagnosed with T1DM, in agreement with Cousminer et al.
(4). Indeed, the authors conclude that the leading genome-wide
signals support the concept of LADA being a late-onset T1DM.
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comparing genetic differences between T1DM and LADA, the
relatively small sample size could limit our ability to detect
minor differences, especially in the group with T1DM diagnosed
after the age of 30 years. For unknown reasons, the number of
male participants exceeds that of females. This may have
inﬂuenced some of the results. Also, we limited our study to
three of the main genes related to T1DM risk. More extensive
studies assessing polygenic risk scores, would be interesting
to perform.
To summarize, we present one of the few studies to directly
compare differences in the genetic proﬁle of patients with T1DM
and LADA. We believe this differentiation is important because
the underlying autoimmune process against the b-cell can have
consequences for the prognosis, complications and treatment of
patients (24). We report a similar T1DM risk allele distribution
in patients with LADA compared to individuals with T1DM
diagnosed after the age of 30, but less risk alleles than in those
diagnosed before the age of 30 years. Our results suggest that,
from a genetic point of view, LADA holds genetic similarities to
late-onset forms of T1DM. Our study supports the importance
of genetic studies in the characterization of LADA, but also of
comparing the study group with appropriate controls, although
the conﬁdence in the results is limited by sample size.

frequency of protective HLA genotypes is a speciﬁc feature of
patients with slowly-progressing T1DM. We did not ﬁnd
signiﬁcant differences in genotypes when comparing LADA
and T1DM with onset after 30 years of age, although given the
low number of patients in the >30 years age group compared to
the overall T1DM population we cannot rule out the existence of
differences. Indeed, other authors have reported differences
between these two groups (18, 24).
The presence of the T allele in rs2476601 in PTPN22 has
been reported to increase the risk of T1DM (20, 26) and LADA
(17, 25) by some authors, though it is not a generalized ﬁnding in
the latter (20). Studies focused on evaluating the differences
between its frequency in patients with T1DM and patients with
LADA are scarce. We found the risk variant more frequently in
patients diagnosed with T1DM before de age of 30 years than in
those with LADA, even though the result was statistically
borderline (p=0.045). No differences were found on those
diagnosed after the age of 30 (see Table 4). Authors have
reported an increased presence of the risk (T) allele in both
patients with T1DM and LADA when compared to healthy
controls (17). Dong et al. reported a similar effect of the PTPN22
gene (rs2476601) in their 2014 meta-analysis, when comparing
patients diagnosed with LADA with healthy controls. They
found an increased risk for LADA in carriers of the risk allele
(21). Similarly, this T allele has also been shown to confer an
increased risk of T1DM (5, 25–27).
On the other hand, Kisand et al. (20) reported no association
between PTPN22 genotypes and LADA susceptibility, but did
ﬁnd an increased risk for T1DM associated to rs2476601, when
comparing both types of DM with controls. Interestingly, there
was a 30-year difference in the mean age of diagnosis between
the groups. In their 2019 meta-analysis, Ramu et al. (22) also
compared subjects with LADA and healthy controls, and
reported a signiﬁcant association for the risk allele in
rs2476601 with LADA in the codominant, dominant and
recessive models.
Regarding the INS rs689 SNP, we also found a different
genotypic distribution among our patients, with a reduced
frequency of the (T) minor allele in patients diagnosed with
T1DM when compared with LADA or T2DM, though no
signiﬁcant difference was seen between LADA and T1DM
patients with an onset of >30 years (see Table 4). Kisand et al.
(19) reported similar ﬁndings after comparing their patients
with T1DM, T2DM and LADA. The T allele was associated with
a reduced risk of T1DM, but was not associated with the risk of
LADA. In their meta-analysis, Ramu et al. (22) also showed an
inverse association between LADA and the presence of the T
allele in the codominant, dominant and recessive models.
We acknowledge this study has some limitations. Even
though our study is one of the largest published to date
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